BioDelivery Sciences International Inc., a pharmaceutical company focusing on pain management and addiction medicine, reported a fourth-quarter loss that was worse than expected but reported revenue that was better than Wall Street expectations.

The Raleigh-based company reported a net loss of $16.2 million, or 29 cents per share, in the fourth quarter, compared to a net loss of $15.9 million, or 29 cents per share, in the fourth quarter of 2016. Analysts were expecting a loss of 22 cents.

Revenue for the fourth quarter was $12.5 million, up 220 percent from revenue of $3.9 million in the third quarter of 2016. Analysts were expecting revenue of $9.8 million.

Its Belbuca drug reported net revenue of $9.4 million in the fourth quarter, a 47 percent increase from the previous year.

“The momentum we experienced with Belbuca in 2017 has extended into 2018, as we reached an all-time high in monthly prescriptions of over 8,600 prescriptions in January and are on track for strong results in February following the highest 4-week total in prescriptions we have seen to date,” said President Scott Plesha in a statement.

The company recently signed a commercial license with Humana, the second-largest Medicare provider, adding Belbuca as a preferred prescription. It has also recently increased its sales representatives from 65 to 85.

BioDelivery Sciences utilizes technology and other drug delivery technologies to develop and commercialize new applications of proven therapies aimed at addresses important unmet medical needs.

The company’s products, such as Belbuca. address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, and opioid dependence.

BioDelivery’s shares were trading at $2.12, down 8 cents, in Friday afternoon trading.

The earnings filing can be found here.